Cargando…

Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model

INTRODUCTION: Triple-negative breast cancer (TNBC) is a highly aggressive subtype with a poor prognosis. Current single-agent checkpoint therapy has limited effectiveness in TNBC patients. In this study, we developed doxorubicin-loaded platelet decoys (PD@Dox) for chemotherapy and induction of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Hang, Gao, Meng, Lu, Lu, Gui, Rong, Fu, Yunfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319348/ https://www.ncbi.nlm.nih.gov/pubmed/37409026 http://dx.doi.org/10.2147/IJN.S403339

Ejemplares similares

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
por: Chen, Mo, et al.
Publicado: (2022)

Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
por: Gao, Tong, et al.
Publicado: (2023)

A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy
por: Yang, Zhaoxuan, et al.
Publicado: (2022)

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles
por: Da Silva, Candido G., et al.
Publicado: (2019)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer
por: Guo, Beibei, et al.
Publicado: (2023)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery
por: Kholod, Olha, et al.
Publicado: (2022)

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
por: Lothstein, Leonard, et al.
Publicado: (2020)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop
por: Wu, Yu-Wen, et al.
Publicado: (2020)

Therapeutic Effect of Doxorubicin-Chlorin E6-Loaded Mesoporous Silica Nanoparticles Combined with Ultrasound on Triple-Negative Breast Cancer
por: Xu, Peng, et al.
Publicado: (2020)

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer
por: Casas, Geoffrey, et al.
Publicado: (2022)

Synthesis, Characterization, and In Vitro Cytotoxicity Evaluation of Doxorubicin-Loaded Magnetite Nanoparticles on Triple-Negative Breast Cancer Cell Lines
por: Markhulia, Jano, et al.
Publicado: (2023)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Decoy Exosomes Offer Protection Against Chemotherapy‐Induced Toxicity
por: Fan, Miao, et al.
Publicado: (2022)

Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells
por: Wu, Di, et al.
Publicado: (2019)

Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells
por: Fathy Abd-Ellatef, Gamal-Eldein, et al.
Publicado: (2020)

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
por: Mamot, Christoph, et al.
Publicado: (2023)

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines
por: Rao, Lang, et al.
Publicado: (2020)

MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer
por: Cao, Zhiwen, et al.
Publicado: (2023)

Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer
por: Wang, Zhicheng, et al.
Publicado: (2021)

DecoyFinder, a tool for finding decoy molecules
por: Adrià, Cereto Massagué, et al.
Publicado: (2012)

Inhaled platelet vesicle-decoyed biomimetic nanoparticles attenuate inflammatory lung injury
por: Jin, Hua, et al.
Publicado: (2022)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

Aptamer-Mediated Codelivery of Doxorubicin and NF-κB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells
por: Porciani, David, et al.
Publicado: (2015)

Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer
por: Gu, Fenfen, et al.
Publicado: (2022)

Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma
por: Xu, Peipei, et al.
Publicado: (2017)

High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer
por: Lin, Hsin-Che, et al.
Publicado: (2019)

α‐Synuclein decoy peptide protects mice against α‐synuclein‐induced memory loss
por: Guo, Qingyun, et al.
Publicado: (2023)

Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy
por: Wang, Meng, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_59p0v2fkvkuregle1lnevsn66t